Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 4376720, 5 pages
http://dx.doi.org/10.1155/2016/4376720
Clinical Study

Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer

1Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, No. 600 Yi Shan Road, Shanghai 200233, China
2Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, No. 600 Yi Shan Road, Shanghai 200233, China

Received 17 August 2015; Revised 17 November 2015; Accepted 17 November 2015

Academic Editor: Yu-Chang Tyan

Copyright © 2016 Liyan Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Seidlin, L. D. Marinelli, and E. Oshry, “Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid,” The Journal of the American Medical Association, vol. 132, pp. 838–847, 1946. View at Google Scholar
  2. D. Van Nostrand, “The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer,” Thyroid, vol. 19, no. 12, pp. 1381–1391, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Markitziu, J. Lustmann, B. Uzieli, Y. Krausz, and R. Chisin, “Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer,” Oral Surgery, Oral Medicine, Oral Pathology, vol. 75, no. 3, pp. 318–322, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Alexander, J. B. Bader, A. Schaefer, C. Finke, and C.-M. Kirsch, “Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma,” Journal of Nuclear Medicine, vol. 39, no. 9, pp. 1551–1554, 1998. View at Google Scholar · View at Scopus
  5. W.-Y. Lin, Y.-Y. Shen, and S.-J. Wang, “Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients,” Clinical Nuclear Medicine, vol. 21, no. 10, pp. 780–782, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. B. L. Malpani, A. M. Samuel, and S. Ray, “Quantification of salivary gland function in thyroid cancer patients treated with radioiodine,” International Journal of Radiation Oncology Biology Physics, vol. 35, no. 3, pp. 535–540, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. K. H. Bohuslavizki, W. Brenner, S. Lassmann et al., “Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine,” Nuclear Medicine Communications, vol. 17, no. 8, pp. 681–686, 1996. View at Publisher · View at Google Scholar
  8. J. P. Almeida, Á. E. Sanabria, E. N. P. Lima, and L. P. Kowalski, “Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer,” Head and Neck, vol. 33, no. 5, pp. 686–690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Jentzen, E. Schneider, L. Freudenberg et al., “Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer,” Nuclear Medicine Communications, vol. 27, no. 8, pp. 669–676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Van Nostrand, J. Neutze, and F. Atkins, “Side effects of ‘rational dose’ iodine-131 therapy for metastatic well-differentiated thyroid carcinoma,” Journal of Nuclear Medicine, vol. 27, no. 10, pp. 1519–1527, 1986. View at Google Scholar · View at Scopus
  11. P. Allweiss, G. D. Braunstein, A. Katz, and A. Waxman, “Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication,” Journal of Nuclear Medicine, vol. 25, no. 7, pp. 755–758, 1984. View at Google Scholar · View at Scopus
  12. G. DiRusso and K. A. Kern, “Comparative analysis of complications from I-131 radioablation for well-differentiated thyroid cancer,” Surgery, vol. 116, no. 6, pp. 1024–1030, 1994. View at Google Scholar · View at Scopus
  13. R. S. Benua, N. R. Cicale, M. Sonenberg, and R. W. Rawson, “The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer,” The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine, vol. 87, pp. 171–182, 1962. View at Google Scholar
  14. D. Van Nostrand and J. Freitas, “Side effects of I-131 for ablation and treatment of well-differentiated thyroid carcinoma,” Thyroid, vol. 19, pp. 1381–1391, 2009. View at Google Scholar
  15. M. Caglar, M. Tuncel, and R. Alpar, “Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment,” Clinical Nuclear Medicine, vol. 27, no. 11, pp. 767–771, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. E. E. Pochin, “Radioiodine treatment of thyroid cancer,” in Therapeutic Use of Artificial Radioisotopes, P. F. Hahn, Ed., John Wiley & Sons, 1956. View at Google Scholar
  17. P. W. Craswell, “Vocal cord paresis following radioactive iodine therapy,” British Journal of Clinical Practice, vol. 26, no. 12, pp. 571–572, 1972. View at Google Scholar · View at Scopus
  18. S. Snyder, “Vocal cord paralysis after radioiodine therapy,” Journal of Nuclear Medicine, vol. 19, no. 8, pp. 975–976, 1978. View at Google Scholar · View at Scopus
  19. A. M. Robson, “Vocal cord paralysis after treatment of thyrotoxicosis with radioiodine,” British Journal of Radiology, vol. 54, no. 643, article 632, 1981. View at Publisher · View at Google Scholar · View at Scopus
  20. T. C. Lee, J. C. Harbert, S. W. Dejter, D. R. Mariner, and J. VanDam, “Vocal cord paralysis following I-131 ablation of a postthyroidectomy remnant,” Journal of Nuclear Medicine, vol. 26, no. 1, pp. 49–50, 1985. View at Google Scholar · View at Scopus